Biallelic pathogenic variants in the CTC1 gene are associated with cerebroretinal microangiopathy with calcifications and cysts (CRMCCs), also known as Coats plus syndrome (CPS; OMIM #612199). This rare multisystem condition is characterized by early childhood onset of intracranial calcifications, leukodystrophy and cysts, along with retinal telangiectasia and exudates (Coats disease). We report a woman referred to genetics with complex multisystem clinical manifestations beginning in her 30s and progressing over two decades. In keeping with classical features of the condition, she presented a complex medical history of pathological bone fractures, gastrointestinal ectasias, and premature aging. In addition, she developed progressive thrombotic microangiopathy-associated kidney disease requiring transplantation, suspected liver cirrhosis, and subcutaneous dystrophic calcifications. Exome sequencing identified compound heterozygous likely pathogenic variants in CTC1, consisting of a previously reported missense variant and a novel truncating variant confirmed in trans. Despite clinical features suggestive of premature aging, telomere length analysis demonstrated low-normal values for age, supporting emerging evidence that telomere shortening is not a consistent feature of CTC1-related disorders. This case represents the second confirmed adult-onset CTC1-related disorder and the longest survival to date. The findings suggest that subcutaneous calcifications and progressive renal and multi-organ disease may represent later-onset manifestations of the condition. TMA may be a pathologic feature of the multi-system impacts of this rare disease in adults.
Élisabeth C Soubry, J. K. Postma, Meredith K. Gillespie et al.· American Journal of Medical...· 0 citations
With sustained investment and a national vision, Canada has the potential to create a more integrated and effective system for managing rare diseases. In the first article in this series, we argued that Canada needs to move toward a genomics-informed learning health system for rare disease (RD); one in which diagnosis, care, discovery, and patient outcomes are connected in a continuous cycle of learning. Canada possesses many of the foundational components. Across the country, clinicians, clinician-scientists, and researchers have developed innovative programs and infrastructure. However, these initiatives are too often supported through short-term funding cycles and limited budgets that are insufficient to sustain, scale, or integrate successful programs over the long term. At the same time, funding structures often prioritize new initiatives over the expansion and coordination of existing ones, contributing to duplication of effort and a tendency to reinvent the wheel.
K. Boycott, E. Price, M. Osmond et al.· Open Access Government· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.